Plant Name: Nectandra rubra
Taxonomic Information:
Plant ID: NPO4861
Plant Latin Name: Nectandra rubra
Taxonomy Genus: Nectandra
Taxonomy Family: Lauraceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| ACHE; | |
| TDP1; PKM; HSD17B1; NOX4; ALOX15; USP2; TNKS; TNKS2; APEX1; POLB; | |
| CFTR; | |
| GSK3B; SYK; FLT3; CDK6; CSNK2A1; | |
| AR; | |
| ESR2; ESR1; | |
| MAOA; PTGS2; XDH; | |
| HIF1A; TP53; | |
| ABCG2; ABCC1; | |
| NPC1; MCL1; MAPT; THPO; TTR; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.322E-12 | 1.808E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.457E-12 | 1.941E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.544E-10 | 2.586E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4, NOX4, PTGS2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 9.196E-10 | 9.798E-07 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4, XDH |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 4.075E-09 | 2.862E-06 | AR, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 1.892E-08 | 8.958E-06 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.516E-07 | 4.926E-05 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 9.043E-07 | 2.212E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 9.973E-07 | 2.382E-04 | MAPT, NOX4, PTGS2, TP53, XDH |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 1.242E-06 | 2.787E-04 | AR, CYP19A1, ESR1 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.653E-06 | 3.596E-04 | CYP1A2, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.756E-06 | 3.750E-04 | ABCG2, ACHE, CSNK2A1, ESR1, ESR2, FLT3, MAPT, MCL1, PKM, PTGS2, TP53, TTR, USP2, XDH |
| MF | GO:0005488; binding | GO:0019899; enzyme binding | 2.021E-06 | 4.191E-04 | AR, CFTR, CYP1A1, CYP1A2, CYP3A4, ESR1, ESR2, GSK3B, HIF1A, MAPT, POLB, PTGS2, SYK, TNKS2, TP53, USP2 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 3.972E-06 | 7.330E-04 | APEX1, POLB |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 3.972E-06 | 7.330E-04 | ESR1, ESR2 |
| BP | GO:0008152; metabolic process | GO:0031324; negative regulation of cellular metabolic process | 5.369E-06 | 9.506E-04 | APEX1, AR, CSNK2A1, CYP2D6, ESR1, ESR2, GSK3B, HIF1A, MAPT, MCL1, NPC1, PTGS2, TNKS, TNKS2, TP53, USP2, XDH |
| BP | GO:0032502; developmental process | GO:0007568; aging | 6.430E-06 | 1.103E-03 | APEX1, CYP1A1, NOX4, POLB, PTGS2, TP53 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 7.475E-06 | 1.262E-03 | AR, CDK6, CSNK2A1, ESR1, FLT3, HIF1A, PTGS2, SYK, THPO, TSHR |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 9.869E-06 | 1.640E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 9.869E-06 | 1.640E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0014074; response to purine-containing compound | 1.078E-05 | 1.765E-03 | APEX1, CFTR, NOX4, PTGS2, TP53 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.190E-05 | 1.864E-03 | CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 1.190E-05 | 1.864E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.190E-05 | 1.864E-03 | CYP1A1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 1.235E-05 | 1.920E-03 | CYP1A1, HIF1A, NOX4, PKM, PTGS2, TP53 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.311E-05 | 2.024E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:1901216; positive regulation of neuron death | 1.727E-05 | 2.558E-03 | GSK3B, MAPT, MCL1, TP53 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 1.916E-05 | 2.819E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 1.998E-05 | 2.920E-03 | APEX1, CDK6, CFTR, CYP1B1, PTGS2, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 2.152E-05 | 3.104E-03 | CYP1B1, HIF1A, PTGS2 |
| MF | GO:0005488; binding | GO:0008013; beta-catenin binding | 2.216E-05 | 3.159E-03 | AR, CSNK2A1, ESR1, GSK3B |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 2.377E-05 | 3.177E-03 | TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.377E-05 | 3.177E-03 | CYP1A1, CYP1A2 |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 2.389E-05 | 3.177E-03 | CYP1B1, GSK3B, MAPT, MCL1, NOX4, PTGS2, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 2.407E-05 | 3.177E-03 | CYP19A1, CYP3A4, ESR1 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 2.377E-05 | 3.177E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.377E-05 | 3.177E-03 | CYP1A2, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 2.623E-05 | 3.401E-03 | ALOX15, GSK3B, HIF1A, MAPT, NOX4, TNKS, TNKS2, TP53 |
| MF | GO:0005488; binding | GO:0046983; protein dimerization activity | 2.670E-05 | 3.440E-03 | ABCG2, ACHE, AR, FLT3, HIF1A, MAPT, MCL1, PTGS2, TP53, TTR, XDH |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 3.289E-05 | 4.093E-03 | ABCC1, ALOX15, SYK |
| CC | GO:0044464; cell part | GO:0005739; mitochondrion | 3.368E-05 | 4.167E-03 | APEX1, CYP1A1, CYP1B1, CYP2D6, ESR2, GSK3B, MAOA, MCL1, NOX4, PKM, TP53 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 3.624E-05 | 4.409E-03 | CSNK2A1, HIF1A, MAPT |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 3.957E-05 | 4.708E-03 | CYP1A1, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0034097; response to cytokine | 4.212E-05 | 4.958E-03 | ALOX15, FLT3, GSK3B, HIF1A, MCL1, PTGS2, TP53 |
| BP | GO:0051179; localization | GO:0051222; positive regulation of protein transport | 4.383E-05 | 5.103E-03 | ACHE, CFTR, GSK3B, HIF1A, PTGS2, SYK, TP53 |
| BP | GO:0051179; localization | GO:0060341; regulation of cellular localization | 5.231E-05 | 5.995E-03 | AR, CFTR, CSNK2A1, GSK3B, HIF1A, MAPT, PTGS2, SYK, TP53 |
| BP | GO:0008152; metabolic process | GO:0046456; icosanoid biosynthetic process | 5.638E-05 | 6.361E-03 | ALOX15, PTGS2, SYK |
| CC | Unclassified; | GO:0043234; protein complex | 5.742E-05 | 6.445E-03 | APEX1, AR, CDK6, CFTR, CSNK2A1, ESR1, FLT3, GSK3B, HIF1A, MAPT, MCL1, POLB, PTGS2, SYK, TNKS, TP53, TTR |
| BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 5.898E-05 | 6.552E-03 | APEX1, GSK3B, PKM, TP53, TSHR |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 5.928E-05 | 6.552E-03 | CYP1A1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0043410; positive regulation of MAPK cascade | 6.422E-05 | 7.063E-03 | ALOX15, AR, FLT3, NOX4, SYK, THPO, XDH |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 6.538E-05 | 7.154E-03 | CYP19A1, CYP1A2, NOX4, XDH |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 7.122E-05 | 7.640E-03 | CFTR, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4, NOX4, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 8.289E-05 | 8.554E-03 | CYP1A1, CYP2D6 |
| MF | GO:0005488; binding | GO:0070324; thyroid hormone binding | 8.289E-05 | 8.554E-03 | PKM, TTR |
| MF | GO:0005215; transporter activity | GO:0008559; xenobiotic transmembrane transporting ATPase activity | 8.289E-05 | 8.554E-03 | ABCC1, ABCG2 |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 8.552E-05 | 8.784E-03 | ALOX15, ESR1, GSK3B, MAPT, TP53 |
| MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 8.635E-05 | 8.827E-03 | AR, ESR1, GSK3B, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.381E-09 | 1.726E-07 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 4.294E-08 | 2.684E-06 | HSD17B1, CYP1A1, CYP1B1, PTGS2, CYP19A1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.946E-07 | 1.228E-05 | CYP2D6, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.072E-06 | 2.681E-05 | MAOA, CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 5.284E-07 | 1.651E-05 | CYP1A2, CYP1A1, CYP1B1, CYP3A4, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.024E-05 | 1.600E-04 | AR, GSK3B, CDK6, FLT3, PTGS2, HIF1A, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 8.661E-06 | 1.600E-04 | PKM, FLT3, TP53, HIF1A |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 9.741E-06 | 1.600E-04 | MAOA, CYP2D6, CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 2.203E-05 | 3.023E-04 | ABCC1, CDK6, CYP1B1, PTGS2, TP53, MCL1 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 4.673E-05 | 4.867E-04 | POLB, CDK6, PKM, SYK, TP53 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 9.763E-05 | 7.627E-04 | PKM, MAOA, HSD17B1, CYP1A2, ALOX15, CYP1A1, PTGS2, CYP3A4, CYP19A1, XDH |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 6.589E-05 | 6.336E-04 | CYP2D6, MAOA, ALOX15, PTGS2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 8.074E-05 | 7.159E-04 | GSK3B, TP53, ESR1, HIF1A |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 1.399E-04 | 1.029E-03 | GSK3B, CDK6, CSNK2A1, TP53 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 2.419E-05 | 3.023E-04 | CYP1A2, ALOX15, CYP3A4 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 5.004E-04 | 2.979E-03 | GSK3B, CDK6, SYK, TP53, MCL1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 3.725E-04 | 2.328E-03 | GSK3B, ESR1, ESR2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 6.300E-04 | 3.424E-03 | GSK3B, SYK, CSNK2A1, TP53 |
| 09130 Environmental Information Processing | 09131 Membrane transport | hsa02010 | ABC transporters | 8.590E-05 | 7.159E-04 | ABCC1, CFTR, ABCG2 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 2.754E-04 | 1.913E-03 | CYP1A2, CYP1A1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 6.933E-04 | 3.611E-03 | GSK3B, AR, TP53 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 3.575E-04 | 2.328E-03 | CYP3A4, CFTR, ABCG2 |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 6.273E-04 | 3.424E-03 | CDK6, PTGS2, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04064 | NF-kappa B signaling pathway | 7.879E-04 | 3.940E-03 | SYK, CSNK2A1, PTGS2 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04110 | Cell cycle | 1.806E-03 | 8.684E-03 | GSK3B, CDK6, TP53 |
| 09120 Genetic Information Processing | 09124 Replication and repair | hsa03410 | Base excision repair | 1.883E-03 | 8.718E-03 | POLB, APEX1 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 3.691E-05 | 4.195E-04 | CYP1A2, XDH |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
